Rivaroxaban: Management of Coronary Artery Thrombosis in a Patient Presenting with Anterior Wall Myocardial Infarction

Coronary artery thrombosis is one of the most common clinically manifested disease that if not treated timely leads to morbidity and mortality particularly stroke or myocardial infarction. Anti-platelets are already the first line of treatment that are adopted for the prevention of coronary artery thrombosis however, there is need of a novel and potent anticoagulant that could help to reduce the frequency of coronary or atherothrombotic events in patients presenting with coronary diseases. Case Summary: We present a case of anterior wall myocardial infarction (AWMI) driven by coronary artery thrombosis. The patient upon diagnosis was found to have a clot in proximal left anterior descending artery (LAD). The patient was treated and discharged on anticoagulation therapy. We examined and report the effectiveness of anticoagulation therapy via a novel oral anticoagulant. i.e. Rivaroxaban for managing the risk of coronary artery thrombosis associated with AWMI within our patient. Onset of coronary artery thrombosis is associated with the mortality in myocardial infarct patients, regardless of its timing. This calls out for the need to manage the disease by adopting strategies that would prevent the frequent onset of these events in myocardial infarction survivors. Treatment with Rivaroxaban has emerged as a promising oral anticoagulant that could potentially serve as a long-term anticoagulant for managing coronary artery thrombosis in patients with heart complications.